Yes, it is time to reconstitute again. Say what? Reconstitute is a buzzword (or is it a fog word?) for restructuring the stocks in the 21 Russell stock indexes.
With $365 billion invested in mutual funds that rely on the Russell indexes as investment models, mutual funds will need to buy the new additions, and sell the deletions, to "rebalance" their holdings. In plain English, "There is going to be sellin' and buyin' goin' on" before the new indexes go into effect at the market close on June 25.
This year's reconstitution of the Russell 3000 -- a market-cap-weighted index made up of the 3,000 largest U.S. companies, representing about 98% of the value of all companies in the U.S. market -- includes the addition of 34 biotechnology firms and 20 medical specialty companies. Examples of these are Keryx Biopharmaceuticals
The 323 additions are not just high-technology companies. There is everything from Motley Fool Hidden Gems Watch List stock and chicken wing purveyor Buffalo Wild Wings
Deletions include 56 banks, regional banks, and savings and loans -- although there are also 15 such financial institutions on the additions list.
So, why should investors care that insurance company Conseco
Yes, there may be short-term buying and selling in the stocks being added or deleted. But, long-term, it is those businesses building value that drive prices higher.
Interested in mutual funds? Take a free 30-day trial to Motley Fool Champion Funds to learn which funds are the best-performing and most efficiently run out there.
Fool contributor W.D. Crotty does not own any of the stocks mentioned.
More from The Motley Fool
What Cryptocurrency Crash? Bitcoin, Ethereum, and Ripple Are Soaring Today
The total cryptocurrency market cap has grown by $150 billion in the past day.
What We Know About the Samsung Galaxy S9
A recent leak tells us nearly everything we want to know about Samsung's upcoming flagship.
3 High-Yield Stocks With Virtual Monopolies
These companies have near-monopolies (or real monopolies in some cases) that generate significant cash flows. But are they enough to make them worth investing in?